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Highlights:
 Serum Hcy was higher in MSA patients when compared to healthy subjects,
particularly in male patients.
 Serum UA was lower in MSA patients when compared healthy subjects, particularly
in male patients.
 Serum Hcy levels were significantly positively correlated with the severity of MSA.
 The ROC curve for the combination of Hcy and UA showed potential diagnostic
value in discriminating MSA from healthy subjects.
Aim: There is evidence suggesting that inflammatory responses play a critical role in the
pathogenesis of multiple system atrophy (MSA). Whether inflammatory mediators can be
used as reliable biomarkers to detect the severity and progression of MSA remains largely
unknown.
Methods:We performed a cross-sectional study that included 47 patients with MSA and
50 healthy age-matched controls. Serum levels of homocysteine (Hcy), uric acid (UA),
and C-reactive protein (CRP) were measured. These levels positively correlated with the
severity of MSA, based on both motor and non-motor symptoms. Several scales were
used to rate the severity of MSA, including the Unifiedmultiple system atrophy rating scale,
Parkinson’s disease sleep scale, Non-motor Symptoms Scale, the Schwab & England
activities of daily living scale, Webster Scale, modified Hoehn and Yahr staging scale, and
the Mini-Mental State Examination. Receiver operating characteristic (ROC) curves was
applied to map the diagnostic accuracy of MSA against healthy subjects.
Frontiers in Cellular Neuroscience | www.frontiersin.org July 2015 | Volume 9 | Article 2471
Chen et al. Hcy and UA in MSA
Results: Compared with healthy subjects, we found that serum Hcy was higher, UA
was lower, and CRP levels were unchanged in MSA patients. These findings were
especially prominent in male patients. No significant differences of serum Hcy and UA
were observed between patients of MSA and PD. Interestingly, there was a significant
correlation betweenHcy levels andMSA severity such asmovement dysfunction, declined
cognition, and cardiovascular symptoms. Additionally, the ROC curve for the combination
of Hcy and UA (AUC 0.736) showed potential diagnostic value in discriminating MSA from
healthy subjects.
Conclusion: Our findings suggest that the inflammatory mediators Hcy and UA may
play important roles in the pathogenesis of MSA. The measurement of serum Hcy and
UA levels could then be a useful tool to accurately distinguish MSA from healthy subjects.
Keywords: multiple system atrophy, homocysteine, uric acid, cognition, inflammation
Introduction
Multiple system atrophy (MSA) is a sporadic, adult-onset, and
progressive neurodegenerative disease. It has neuropathological
features that lead to neuronal loss mainly in the nigrostriatal
pathways, such as the basal ganglia, cerebellum, pons, inferior
olivary nuclei, and spinal cord (Stefanova, 2009). MSA is clinically
characterized as Parkinsonism, cerebellar ataxia, and autonomic
dysfunction; the diseasemanifests as various combinations of cor-
ticospinal tract impairment and urinary symptoms (Gilman et al.,
1999; Kaufman et al., 2013). It has been reported that the inci-
dence of the disease is six patients per 1,000,000 persons per year
(Stefanova, 2009). MSA is divided into three types: Parkinsonism
(MSA-P), cerebellar dysfunction (MSA-C), and autonomic and
urinary dysfunction (MSA-A) (Gilman et al., 1999;Wenning et al.,
2004). There is evidence that a core protein, alpha-synuclein, is
involved in the pathogenesis of MSA. This finding indicates that
the disease may have a similar neuropathological characteristic
to other α-synucleinopathies diseases, such as Parkinson’s disease
(PD) (Kim et al., 2011; Yasuda et al., 2013; Saracchi et al., 2014).
Although the etiology of MSA and PD are poorly understood,
they share a possible pathogenesis and show similar clinical fea-
tures. For instance, both are influenced by motor and non-motor
dysfunctions such as rigidity and cognitive impairment.
Neuroinflammation has been described as an important par-
ticipant in several neurodegenerative diseases including PD,
Alzheimer’s disease (AD), and MSA (Gemma, 2010; Labandeira-
Garcia et al., 2011; Rosano et al., 2012). It has been shown that
the proinflammatory cytokine interleukin 18 (IL-18) is elevated
Abbreviations: AD, Alzheimer’s disease; ADL, the Schwab & England activities of
daily living scale; ALS, amyotrophic lateral sclerosis; AUC, area under the curve;
BBB, blood–brain barrier; CRP, C-reactive protein; CNS, central nervous system;
Hcy, homocysteine; H&Y, modified Hoehn and Yahr staging scale; MMSE, mini-
mental state examination; MSA, multiple system atrophy; MSA-A, multiple system
atrophy-autonomic and urinary dysfunction; MSA-C, multiple system atrophy-
cerebellar dysfunction; MSA-P, multiple system atrophy-parkinsonism; NMDA,
N-methyl--aspartate; NMS, non-motor symptoms; PD, idiopathic Parkinson’s dis-
ease; PDSS, Parkinson’s disease sleep scale; ROC, receiver operating characteristic;
ROS, reactive oxygen species; rs, the Spearman’s rank correlation coefficient; SD,
standard deviation; UA, uric acid; UK-PDSBB, the United Kingdom PD Society
Brain Bank; UMSARS, unified multiple system atrophy rating scale.
in post-mortem AD patient brains, and it modulates the tau
kinases, GSK3β, and Aβ-production, strongly implying that the
chronic inflammation and oxidative stress are closely related to
AD pathogenesis (Sutinen et al., 2014). Abnormal activation of
microglia can cause damage to the brain–blood barrier (BBB)
in the central nervous system (CNS), and the accumulation of
activated microglia and proinflammatory cytokines may accel-
erate and amplify the neuroinflammation in neurodegenerative
diseases such as PD, amyotrophic lateral sclerosis (ALS), and
AD (Bachstetter and Van Eldik, 2010; Paredes et al., 2010; Ben-
dotti et al., 2012; Gordon, 2013; Chaudhari et al., 2014; da Fon-
seca et al., 2014; Takeuchi and Suzumura, 2014). Several lines
of evidence also indicated that neuroimmunomodulation may
be a potential therapeutic strategy in delaying the neurode-
generative process (Gemma, 2010; Carret-Rebillat et al., 2015;
Hardeland et al., 2015). One clinical study by Kaufman et al.
demonstrated that IL-6 and TNF-α were significantly elevated
in MSA patients when compared to healthy controls (Kauf-
man et al., 2013). C-reactive protein (CRP), a very sensitive
and important inflammatory mediator, was been shown to be
a valid predictor of new cardiovascular risks, type 2 diabetes,
ischemic cerebrovascular disease, and PD (Fu et al., 2009; Song
et al., 2009). Homocysteine (Hcy), a sulfur-containing amino
acid, is produced by the interaction of cysteine and methion-
ine and is closely related to cognitive impairment (Rodriguez-
Oroz et al., 2009; Shimomura et al., 2011; Ray et al., 2013).
Although the exact mechanisms are unclear, the evidence sug-
gests that Hcy plays important roles in the modulation of N-
methyl--aspartate (NMDA) receptors, oxidative stress, activa-
tion of caspases, DNA damage, and mitochondrial dysfunction
(Lipton et al., 1997; Outinen et al., 1998; Kruman et al., 2000;
Huang et al., 2001). Uric acid (UA) has gained popularity as a
natural antioxidant and biomarker of oxidant stress. It is well
documented that high levels of serum UA may have a neuropro-
tective role in some neurodegenerative diseases including PD and
ALS (Paganoni et al., 2012; Cao et al., 2013). It is important to
note that there is also evidence against this theory (Kim et al.,
2011). Several studies, including ours, have demonstrated that
some inflammation-related mediators in the peripheral circula-
tion may be used as indicators for the severity of PD (Rodriguez-
Oroz et al., 2009; Song et al., 2009; Pan et al., 2013). To the best
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of our knowledge, there is a paucity of studies that explore the
combined effects of CRP, Hcy, and UA in evaluating patients
with MSA.
This study was performed to investigate whether the
inflammatory-related mediators, CRP, Hcy, and UA, are
associated with the severity and prevalence of MSA. The primary
aim of this study is to compare serum levels of CRP/Hcy/UA
among MSA patients, PD patients, and normal healthy subjects.
The secondary aim is to evaluate whether serum levels of
CRP/Hcy/UA are associated with motor and non-motor
dysfunctions and to identify their associations with different
non-motor symptoms (NMS) domains in MSA. Lastly, our
goal is to determine the diagnostic value of the serum levels of
CRP/Hcy/UA in the patients with MSA.
Materials and Methods
Patients and Ethics Statement
From July 2011 to November 2014, a total of 47 patients with
MSA (31 males and 16 females; mean age SD, 58.74 10.18)
(Table 1) who were admitted to the Department of Neurology
of the Third Affiliated Hospital of Sun Yat-sen University and
the Department of Neurology, Guangdong 999 Brain Hospital,
Guangzhou, China, were enrolled in this cross-sectional study.
The patients were identified according to the consensus criteria
for the clinical diagnosis of MSA (Gilman et al., 1999). Addi-
tionally, 60 patients with PD (34 males and 26 females; mean
age SD, 63.10 10.62) (Table 1) were recruited based on the
United Kingdom PD Society Brain Bank (UK-PDSBB) criteria
(Hughes et al., 1992). A total of 50 healthy age-matched subjects
(27males and 23 females,mean age SD, 55.64 10.82) (Table 1)
were recruited from the outpatient setting as the control group.
All the outpatients (control group) were recruited from the Med-
ical Examination Center in the Third Affiliated Hospital of Sun
Yat-sen University hospital. These subjects did not present with
hypertension, cerebral ischemia, cardiovascular, diabetes, or renal
dysfunction diabetes considering that presentation with any of the
aforementioned diseases may influence the serum levels of UA,
Hcy, and CRP. In addition, any prostate carcinoma-related medi-
ators [prostate-specific antigen (PSA), carcinoembryonic anti-
gen (CEA), or alpha-fetoprotein (AFP)] were initiallymeasured in
this study, and those who have high levels of those mediators were
excluded from this study in order to eliminate the confounding
factors.
This study was approved by the local Ethics Committee of the
Third Affiliated Hospital of Sun Yat-sen University and has been
conducted according to the principle outlined in the Declaration
of Helsinki of 1975 and the National Institute of Health Human
Subjects Policies and Guidance released in January and December
23, 1999, respectively. All participants provided written consent
for the investigation and the consent to measure the levels of
serum CRP, Hcy, and UA and participate in the following stan-
dard assessments: the Unified MSA rating scale (UMSARS), PD
sleep scale (PDSS), NMS scale (NMSS), the Schwab & England
activities of daily living (ADL) scale, Webster scale, modified
Hoehn and Yahr staging scale (H&Y), Mini-Mental State Exam-
ination (MMSE), and unified PD rating scale (UPDRS). All the
assessments were conducted in a blinded manner.
TABLE 1 | Demographic, motor, and non-motor parameters.
Clinical parameters MSA Control PD
Mean (SD) Min Max Mean (SD) Min Max Mean (SD) Min Max
Gender (n)
Male n(%) 31 (66) 27 (54:0) 34 (56:7)
Female n(%) 16 (34) 23 (46:0) 26 (43:3)
Age (years) 58:74 (10:18) 23 79 55:64 (10:82) 38 76 63:10 (10:62) 41 80
UMSARS (total) 36:17 (10:49) 22 65
UPDRS (I) 14:64 (4:43) 8 26
UPDRS (II) 18:96 (6:35) 10 38
UPDRS (IV) 2:81 (0:95) 1 5
H&Y 3:21 (0:81) 2 5 2:18 (0:95) 1 5
MMSE 25:32 (3:42) 13 30 25:68 (3:71) 15 30
PDSS 122:60 (10:90) 93 143 113:58 (13:56) 60 130
NMSS (total) 72:43 (22:88) 26 123 60:18 (47:36) 5 188
Cardiovascular 8:55 (4:36) 0 16 2:97 (3:08) 0 13
Sleep/fatigue 12:26 (6:27) 1 26 13:35 (8:72) 0 36
Mood 13:49 (6:70) 4 30 13:02 (12:80) 0 54
Perceptual problem 1:96 (3:15) 0 10 1:38 (2:89) 0 12
Attention/memory 7:68 (4:40) 0 21 6:32 (6:04) 0 25
Gastrointestina 9:38 (4:73) 0 18 7:30 (5:62) 0 30
Urinar 9:34 (7:95) 0 24 7:03 (7:69) 0 32
Sexual function 3:45 (6:36) 0 24 3:20 (5:92) 0 21
Miscellaneous 7:13 (5:14) 0 18 4:55 (7:36) 0 36
Schwab & England 61:91 (21:02) 0 90 76:67 (12:31) 30 90
Webster 12:72 (3:35) 7 22 14:77 (11:13) 1 90
SD, standard deviation; UMSARS, the unified Parkinson’s disease rating scale part; H&Y, the modified Hoehn and Yahr staging scale; MMSE, mini-mental state examination; PDSS,
parkinson’s disease sleep scale (range of possible scores from 0 to 150), and NMSS, non-motor symptoms scale for Parkinson’s disease (range of possible scores from 0 to 360).
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Study Design
Experienced neurologists were recruited to perform the evalua-
tions and complete the neurological examinations for both the
inpatients and the outpatients. All patients with MSA included in
this study satisfied the criteria outlined inWenning’s study (Wen-
ning and Krismer, 2013); the patients with PD fulfilled the criteria
of the UK-PDSBB (Hughes et al., 1992). The exclusion criteria
were as follows: (1) all patients with disability due to neurological
disorders other than MSA/PD, such as cerebral vascular disease,
the related sequelae, or psychosis; (2) participants with diseases
that could possibly influence NMS including pain syndromes,
advanced diabetes, mellitus, malignancy, renal, hepatic failure
or cardiovascular diseases, severe anemia, or any other acute or
chronic debilitating or life-threatening disease/state; and (3) indi-
viduals who refused to participate in the study. All subjects com-
pleted the following battery of standardized assessment measures:
the UMSARS was used to evaluate motor dysfunction and disease
severity; the scales included a historical review of disease-related
impairments (I, 12 items; the range is 0–48 points; a higher score
representsmore severe disability), detailedmotor examination (II,
14 items; 0–56 points), and a global disability scale (IV) (Geser
et al., 2005). The H&Y and the ADL scales divided patients into
stages on the basis of clinical disability (Kaufman et al., 2013).
The Webster scale (10 items, total score ranging from 0 to 30
points) was applied to assess the degree of motor disability. The
degree of NMS in every patient was measured by the NMSS and
PDSS (Zhang et al., 2011; Pan et al., 2013). Cognitive abilities were
evaluated with theMMSE (Barone et al., 2009; Pfeiffer, 2009). The
typical magnetic resonance imaging (MRI) for MSA patients is
shown in Figure 1. All scales were available and validated for the
Chinese population. The demographics and clinical data of the
subjects are shown in Table 2.
Blood Sampling Measurement
Venous blood samples for CRP, Hcy, and UA measurements
were obtained from all subjects in the study. A total of 5mL of
blood was taken from the patients, and all the measurements were
replicated thrice. The serum was separated within 1 h by centrifu-
gation at 3,000 rpm for 10min. The separated sera were stored
at –30°C until laboratory evaluation took place. The CRP level
was measured by latex immunoturbidimetric assay, according to
Ichihara’s study (Ichihara et al., 2002); the serum level of Hcy was
determined using a solid-phase competitive chemiluminescent
enzyme immunoassay (Rodriguez-Oroz et al., 2009). The UA
level was measured by a Biochemical Analyzer 7180-ISE (Hitachi
High-Technology Science Systems Corporation, Tokyo, Japan)
using the UA assay kit via the URO-PAP method (Sinosource
Biopharmaceutical Inc.) (Pan et al., 2013).
Statistical Analysis
All continuous variables, including age, UMSARS (UMSARS-I,
-II, -IV and the sum of UMSARS-I, -II, and -IV), MMSE,









Male (%) 5 (26:3) 9 (45:0) 2 (25:0)
Female (%) 14 (73:7) 11 (55:0) 6 (75:0)
Age (years) 58:53 (9:07) 57:90 (11:52) 61:38 (9:96)
UMSARS (total) 31:00 (5:96) 40:30 (11:81) 38:13 (11:32)
UPDRS (I) 12:53 (2:70) 16:30 (5:28) 15:50 (3:70)
UPDRS (II) 16:58 (4:19) 21:05 (6:66) 19:38 (8:42)
UPDRS (IV) 2:41 (0:69) 3:00 (1:08) 3:25 (0:89)
H&Y 2:74 (0:81) 3:45 (0:61) 3:75 (0:71)
MMSE 25:58 (4:00) 25:30 (3:16) 24:75 (2:82)
PDSS 123:11 (10:53) 120:80 (12:38) 125:88 (7:57)
NMSS (total) 78:68 (24:76) 66:90 (19:82) 71:38 (24:53)
Cardiovascular 7:11 (3:76) 8:40 (4:62) 12:38 (2:93)
Sleep/fatigue 14:11 (6:84) 11:30 (6:43) 10:25 (3:11)
Mood 14:47 (6:88) 13:35 (6:73) 11:50 (6:55)
Perceptual problem 2:42 (3:50) 2:25 (3:26) 0:13 (0:35)
Attention/memory 8:37 (4:57) 7:85 (4:16) 5:63 (4:47)
Gastrointestina 10:53 (4:64) 9:00 (4:72) 7:63 (4:90)
Urinar 9:53 (7:59) 7:30 (7:23) 14:00 (9:38)
Sexual function 3:68 (5:93) 3:20 (6:96) 3:50 (6:57)
Miscellaneous 11:21 (3:92) 3:75 (3:86) 5:88 (3:72)
Schwab & England 66:84 (20:29) 62:50 (14:82) 48:75 (31:37)
Webster 12:16 (2:43) 13:50 (3:99) 12:13 (3:52)
Daily dose of L-Dopa (mg) 305:26 (77:99)
(MSA-P)
MSA-P, parkinsonism type; MSA-C, cerebellar dysfunction; MSA-A, autonomic and
urinary dysfunction; SD, standard deviation; UMSARS, the unified Parkinson’s disease
rating scale part; H&Y, the modified Hoehn and Yahr staging scale; MMSE, mini-mental
state examination; PDSS, parkinson’s disease sleep scale (range of possible scores from 0
to 150) and NMSS, non-motor symptoms scale for Parkinson’s disease (range of possible
scores from 0 to 360).
FIGURE 1 | Representative MRI images of a patient with MSA. (A) Horizontal and (B) vertical hyperintensities in the pontine also known as “cross sign,” are
shown in T2-weighted images. (C) Angle sign in the brainstem shown in a T2-weighted image. Red arrows indicate abnormalities pertaining to MSA.
Frontiers in Cellular Neuroscience | www.frontiersin.org July 2015 | Volume 9 | Article 2474
Chen et al. Hcy and UA in MSA
TABLE 3 | Comparison of age, CRP, Hcy, and UA among MSA, PD, and normal healthy subjects.
Variable MSA (meanSD) PD (meanSD) Control (meanSD) χ2 p-Value Tukey’s
MSA/PD MSA/Control
Age 58:74 10:18 63:10 10:62 55:64 10:82 13:157 0:000*** 0.089 0:319
CRP 1:70 1:41 1:34 1:09 1:38 1:085 1:289 0:525 0.982 0:402
Hcy 13:28 4:13 12:89 5:70 10:34 3:07 13:74 0:001** 0.897 0:005**
UA 315:28 83:14 291:07 71:21 357:49 87:81 15:64 0:000*** 0.272 0:029*
*p<0.05, **p<0.01, ***p< 0.001.
Kruskal–Wallis test for the comparison among MSA, PD, and normal subjects, Tukey’s post hoc analysis for the comparison in MSA vs. PD or MSA vs. Control.
TABLE 4 | Comparison of CRP, Hcy, and UA between normal subjects and MSA patients according to genders.
Variable MSA (meanSD) Control (meanSD) MSA vs. Control MSA (Male) vs.
(Female)
Value p Value p
CRP Male 1:59 1:39 1:36 0:96  0:722 0:473a
Female 1:90 1:46 1:41 1:24  1:128 0:267b  0:842 0:400a
Hcy Male 14:26 3:67 10:77 2:94 3:746 0:000***b
Female 11:40 4:44 9:96 3:18  0:791 0:429a 2:349 0:023*b
UA Male 337:45 80:86 397:74 84:49  2:705 0:007**a
Female 272:32 71:67 310:24 66:45 1:698 0:098b 2:716 0:009**b
*p<0.05, **p<0.01, ***p< 0.001.
aMann–Whitney U-test.
bStudent’s t-test.
NMSS, PDSS, Webster, CRP, Hcy, and UA, were presented as
the mean SD; all categorical variables, including gender and
subtype (C-type, P-type, or autonomic and urinary dysfunction),
were presented as percentages. The total scores of age, UMSARS,
MMSE, NMSS, PDSS, Webster, CRP, Hcy, and UA were counted
by summing the single items. Statistical significance of differences
between the groups was assessed using the non-parametric data
Mann–Whitney U-test and Kruskal–Wallis test when the data
were not normally distributed; Student’s t-test was used when
the data were normally distributed. Tukey’s post hoc analysis was
conducted to compare the differences of age/CRP/Hcy/UA among
normal subjects, PD and MSA patients. The Spearman’s rank
correlation coefficient (rs) was performed to evaluate correlations
in different clinical parameters. A receiver operating characteristic
(ROC) analysis was conducted to assess the performance of clini-
cal biomarkers (Hcy, UA, and CRP) in the diagnostic accuracy for
this disease. Additionally, the ROC curve for the combination of
Hcy and UA was calculated to screen for a better prognostic tool
using a logistic regression analysis. p-Values <0.05 were deemed
statistically significant and SPSS 13.0 software (Chicago, IL, USA)
was used for the statistical analyses.
Result
Patient Characteristics
This cross-sectional study consisted of 47 MSA [31 males (66%)
and 16 females (34%)], 60 PD patients [34 males (57%) and 26
(43%) females], and 50 healthy subjects [27 males (54%) and 23
females (46%)]. The mean age of MSA, PD and normal con-
trols were 58.74 10.18, 63.10 10.62, and 55.64 10.82, respec-
tively (Table 1). There was no significant difference in the ages
among the MSA patients and normal subjects (58.74 10.18 vs.
55.64 10.82, p= 0.319, Tukey’s test, Table 3), and MSA and
PD patients (63.10 10.62 vs. 58.74 10.18, p= 0.089, Tukey’s
test, Table 3). When the subjects were classified into three sub-
types, the mean ages of MSA patients was 58.53 9.07 (MSA-P),
57.90 11.52 (MSA-C), and 61.38 9.96 (MSA-A). There was
no significant difference between ages among the three types
(p= 0.949, Kruskal–Wallis test; data not shown). The demo-
graphic and clinical data for the subjects are shown in Table 2.
Comparisons of CRP/Hcy/UA between MSA/PD
Patients and Healthy Subjects
In this study, no significant difference of serum CRP levels among
patients with MSA, PD patients, and healthy subjects (Table 3)
was observed. However, significant differences of serum Hcy
were found among PD, MSA, and the controls (**p= 0.001,
Kruskal–Wallis test, Table 3). The serum Hcy in MSA was
higher than that in normal subjects (13.28 4.13 vs. 10.34 3.07,
**p= 0.005, Tukey’s test, Table 3), but no significant difference
in the Hcy levels between MSA and PD patients was found.
Furthermore, the UA levels in patients with MSA were signifi-
cantly lower than that in the healthy subjects (315.28 83.14 vs.
357.49 87.81, *p= 0.029, Tukey’s test, Table 3). However, our
data showed no significant differences in the CRP, Hcy, and UA
levels among patients with MSA and PD (Table 3).
When MSA patients and healthy subjects were divided into
specific gender groups, the serum levels of Hcy in the male
patients with MSA were higher than that of the normal male
subjects (14.26 3.67 vs. 10.77 2.94, ***p= 0.000, Student’s t-
test, Table 4). Similarly, a significant difference was observed in
plasma UA levels of MSAmale patients and normal male subjects
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FIGURE 2 | Comparison of CRP, Hcy, and UA levels between MSA and
control patients, according to gender. (A) Comparison of CRP between
control and MSA groups. No significant differences of CRP levels were found
between MSA vs. control, MSA (male) vs. control (male), MSA (female) vs.
control (female) and MSA (male) vs. MSA (female). (B) Comparison of Hcy
between control and MSA groups. ***MSA (male) vs. control (male), p<0.001;
MSA (male) vs. MSA (female), p= 0.023; ##MSA vs. control, p= 0.002.
(C) Comparison of UA between control and MSA groups. **MSA (male) vs.
control (male), p= 0.007; MSA (male) vs. MSA (female), p=0.009; ##MSA vs.
control, p= 0.011.
TABLE 5 | Spearman’s rank correlation coefficient (rs) and p-values between clinical variables and H&Y, MMSE, PDSS, NMSS (total/domain), Schwab &
England, and Webster tests.
Variable CRP Hcy UA
r p r P r p
UMSARS(total) 0:363 0:012* 0:193 0:195 0:067 0:653
UMSARS(I) 0:326 0:025* 0:096 0:521 0:169 0:256
UMSARS(II) 0:091 0:541 0:173 0:246 0:135 0:367
UMSARS(IV) 0:419 0:003** 0:327 0:025* 0:079 0:595
H&Y 0:342 0:019* 0:315 0:031* 0:169 0:255
MMSE  0:388 0:007**  0:364 0:012* 0:085 0:571
PDSS  0:047 0:755  0:031 0:836  0:025 0:867
NMSS (total) 0:241 0:103 0:004 0:977 0:062 0:681
Cardiovascular 0:357 0:014* 0:354 0:015**  0:205 0:168
Sleep/Fatigue 0:153 0:303  0:230 0:120  0:112 0:452
Mood 0:226 0:127 0:104 0:485 0:155 0:299
Perceptual problem 0:336 0:021*  0:109 0:466 0:037 0:807
Attention/memory 0:089 0:554  0:009 0:950  0:158 0:289
Gastrointestina 0:114 0:446  0:142 0:341  0:069 0:645
Urinar 0:045 0:763  0:020 0:894 0:016 0:915
Sexual function 0:219 0:140 0:029 0:846 0:177 0:233
Miscellaneous  0:167 0:263  0:139 0:352  0:186 0:212
Schwab & England  0:370 0:011*  0:223 0:133  0:104 0:487
Webster 0:231 0:118 0:230 0:119 0:070 0:642
Daily dose of L-Dopa (mg) 0:410 0:081  0:023 0:897  0:028 0:911
*p<0.05, **p<0.01.
rs, Spearman’s rank correlation coefficient; UMSARS, the unified Parkinson’s disease rating scale part; H&Y, the modified Hoehn and Yahr staging scale; MMSE, mini-mental state
examination; PDSS, parkinson’s disease sleep scale and NMSS, non-motor symptoms scale for Parkinson’s disease.
(337.45 80.86 vs. 397.74 84.49, **p= 0.007, Mann–Whitney
U-test, Table 4). Interestingly, there was no significant differ-
ence between both Hcy and UA levels in female MSA patients
and healthy female subjects. Additionally, the level of Hcy
in male MSA patients was higher than that in the female
patients (14.26 3.67 vs. 11.40 4.44, *p= 0.023, Student’s t-
test, Table 4); the serum UA levels in male patients were higher
than those in female patients with MSA (337.45 80.86 vs.
272.32 71.67, **p= 0.009, Student’s t-test, Table 4). On the
contrary, no significant differences in serum CRP levels were
observed between the MSA patients and healthy subjects; there
were also no significant differences in the serum CRP levels
between male MSA patients and female MSA patients (Table 4;
Figure 2).
Correlations between CRP, Hcy, UA Levels and
UMSARS, H&Y, MMSE, PDSS, NMSS, Schwab &
England, and Webster
To evaluate the correlations between the severity of the disease
and clinical variables, we conducted Spearman’s correlation anal-
ysis between the inflammatory-related mediators and various
assessments. Therewere significant correlations betweenCRP and
UMSARS-I (rs= 0.326, *p= 0.025, Table 5), CRP and UMSARS-
IV (rs= 0.419, **p= 0.003, Table 5), CRP and UMSARS-total
(rs= 0.363, *p= 0.012, Table 5), CRP and H&Y (rs= 0.342,
*p= 0.019, Table 5), CRP and MMSE (rs= 0.388, **p= 0.007,
Table 5), and CRP and Schwab & England (rs= 0.370,
*p= 0.011, Table 5). Although no significant correlations were
observed between CRP and UMSARS-II, CRP and PDSS, CRP
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FIGURE 3 | ROC curves to evaluate the utility of serum levels of CRP,
UA, and Hcy for the discrimination of MSA patients from healthy
controls. The AUC of ROC curves for (A) CRP, (B) Hcy, and (C) UA were
0.550 (95% CI: 0.434–0.666, p= 0.396), 0.709 (95% CI: 0.604–0.813,
***p<0.001), and 0.638 (95% CI: 0.527–0.749, *p=0.019), respectively. The
AUC of (D) Hcy+UA was 0.736 (95% CI: 0.638–0.834, ***p<0.001).
and Webster, CRP and some of burdens of NMSS, there were
significant correlations between CRP and NMS burdens of car-
diovascular (rs= 0.357, *p= 0.014, Table 5) as well as per-
ceptual problem (rs= 0.336, *p= 0.021, Table 5). Meanwhile,
significant correlations were observed between plasma Hcy
and UMSARS-IV (rs= 0.327, *p= 0.025, Table 5), Hcy and
H&Y (rs= 0.315, *p= 0.031, Table 5), and Hcy and MMSE
(rs= 0.364, *p= 0.012, Table 5) in MSA patients. In the
nine domains of NMSS, we also found significant correla-
tions between Hcy and NMS burden of cardiovascular in MSA
patients (rs= 0.354, *p= 0.015, Table 5). There were however, no
significant correlations between Hcy and UMSARS-I, Hcy and
UMSARS-II, Hcy and UMSARS-total, Hcy and PDSS, Hcy and
Schwab & England, Hcy and Webster, Hcy and other NMS bur-
dens in MSA patients. No significant correlations were observed
inUA andUMSARS (I/II/IV/total), UA andH&Y,UA andMMSE,
UA and PDSS, UA and total/nine domains of NMSS, UA and
Schwab & England, UA and Webster among MSA patients. Inter-
estingly, our results also showed that 20 patients with MSA-
P subtype were treated with L-dopa; however, L-dopa was not
significantly correlated to the serum levels of Hcy, UA, and CRP
(Table 5). This finding strongly suggests that L-dopa medication
in MSA would not influence the validation of Hcy/UA/CRP
assessment in MSA.
The ROC Curve of CRP, Hcy, and UA in the
Diagnosis of MSA
A ROC curve was conducted to explore whether CRP, Hcy,
and UA could provide credible discrimination between MSA
patients and normal subjects. The ROC of Hcy analysis revealed
that an area under the curve (AUC) value of 0.709 (95% CI:
0.604–0.813, ***p< 0.001, Figure 3B) was observed; the cutoff
was at 13.68µmol/L, with a sensitivity of 53% and specificity of
90%. The AUC of UAwas 0.638 (95% CI: 0.527–0.749, *p= 0.019,
Figure 3C); the cutoff was at 318.65µmol/L, with a sensitivity of
64% and specificity of 66%. However, the AUC of CRP was 0.550
(95% CI: 0.434–0.666, p= 0.396, Figure 3A), indicating a non-
significant difference. Furthermore, the AUC of the combination
of Hcy and UA was 0.736 (95% CI: 0.638–0.834, ***p< 0.001,
Figure 3D), with a sensitivity of 74% and a specificity of 60% at
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the cutoff of 0.43 on the predicted risk algorithm, indicating that
this combination variable was more robust than Hcy or UA alone
in distinguishing MSA patients from healthy controls.
Discussion
We found several interesting results in this study. First, we found
a pronounced increase in the serum levels of Hcy and decrease
in the levels of UA in MSA patients when compared to normal
subjects. Second, the Hcy serum levels in male MSA patients
were significantly higher than in male normal subjects; the UA
serum levels were significantly lower than in male normal sub-
jects. Third, the ROC curve analysis strongly indicated that the
combination ofHcy andUA could significantly discriminateMSA
patients from normal subjects and be applied as a new screening
diagnosis instrument. The incorporated serum levels of Hcy and
UA can lead to high yields and increase the diagnostic accuracy for
differentiating MSA patients from healthy subjects. To the best of
our knowledge, this is the first study exploring the association of
serum Hcy/UA/CRP levels with the prevalence of MSA.
MSA is a neurodegenerative disease with an unknown etiol-
ogy and pathogenesis. Therefore, it is important to explore the
mechanisms of disease and specific biomarkers in evaluating the
severity and progression of the disease with regard to motor and
non-motor dysfunctions. There is evidence that inflammatory
responses may be involved in the pathogenesis of neurodegenera-
tive diseases such as AD, PD, ALS, and MSA (Wyss-Coray, 2002;
Bachstetter and Van Eldik, 2010; Reese and Taglialatela, 2010;
Sekiyama et al., 2012). There are similarities between PD andMSA
including an abnormal accumulation of α-synuclein protein, a
progressive disease course, and impaired motor and non-motor
functions. According to previous studies, inflammatorymediators
including CRP and Hcy may be used as biomarkers in evaluating
the severity and progression of PD (Lindqvist et al., 2012; Shtil-
bans and Henchcliffe, 2012). Therefore, we examined whether
those same inflammatory mediators may also be employed as
viable and reliable biomarkers in assessing MSA. The associations
between the inflammatory mediators and disease severity were
explored in the current study. We also identified clinical variables
that associated with MSA in different gender groups.
Our results showed no significant difference in serum CRP
levels among MSA patients, PD patients, and healthy subjects.
This finding is different from the changes of serum CRP in PD
and AD; there are increased levels of CRP in PD and reduced
levels in AD (Song et al., 2009; O’Bryant et al., 2010). Although
serum CRP levels in MSA were higher than those in healthy sub-
ject controls, there was no statistically significant difference. One
possible explanation may be that the elevation of CRP in the CNS
is not high enough to affect its peripheral concentration in MSA
patients (Chen et al., 2007). On the other hand, a study byAndican
et al. showed that higher CRP levels only occur in the early stage of
H&Y II in PD patients (Andican et al., 2012). In the current study,
MSA patients recruited were far beyond the H&Y II stage. Serum
levels of Hcy in these patients were significantly higher than those
in healthy subjects, which is similar to other neurodegenerative
diseases such as AD and PD (Zoccolella et al., 2010; Zhang et al.,
2011; Ray et al., 2013; Kim and Lee, 2014). When compared to the
healthy controls, the increased Hcy levels in MSA patients imply
that Hcy contributes to the pathophysiological mechanism in the
disease process; Hcy-mediated oxidative stress plays an important
role in the pathogenesis ofMSA. The precise mechanisms of Hcy’s
neurotoxicity in MSA have not yet been elucidated, but we theo-
rize that the higher levels of Hcy in MSAmay damage endothelial
cells. This can induce the damage of the BBB and lead to the
generation of reactive oxygen species (ROS), which subsequently
promotes the release of inflammatory cytokines and induces
apoptosis (Harrison andDexter, 2013; Kamat et al., 2013; Caldeira
et al., 2014). It has been well documented that both CRP and Hcy
have been reported to be associated with a high risk of prostate
cancer, which usually occurs in elderly male persons. Higher
serumHcy can independently predict the risk of early biochemical
recurrence and aggressiveness of prostate cancer (Stabler et al.,
2011). Several lines of evidence also indicated that the elevated
serum CRP levels were correlated to the high risk of prostate can-
cer and its assessment (Toriola et al., 2013; Thurner et al., 2015).
Therefore, in the diagnosis and evaluation of MSA, those with
high serum levels of PSA, CEA, or AFP were unsuitable for this
study.
Interestingly, we observed no significant difference in the
serum Hcy levels between MSA and PD patients. This finding
supports the point that there may be similarities between the
neuropathogenesis of MSA and the PD. Previous studies have
demonstrated that serum levels of UA are closely correlated to the
severity of dopaminergic impairment in PD (Moccia et al., 2014).
As a natural anti-oxidative stress substance, high levels of UA
may protect neurons from apoptosis in MSA patients (Chen et al.,
2013; Schwarzschild et al., 2014). Similar results have also been
observed in PDpatients (Pan et al., 2013; Simon et al., 2014). These
findings strongly suggest that lower levels of UA may contribute
to the severity of PD and MSA due to the reduced anti-oxidative
protective effects; therefore, UA may be a possible modifier in
MSA (Kim et al., 2011).
After dividing the subjects according to genders, we saw
interesting observations when comparing MSA patients and
healthy subjects (Table 4; Figure 2). Serum Hcy and UA levels
in male MSA patients were significantly higher than female MSA
patients. One possible reason is that males express more negative
risk factors for disease such as smoking, drinking, and unhealthy
diets than females (Baccarelli et al., 2007; Sobczak et al., 2007;
Lee et al., 2010). These factors may upregulate baseline Hcy
levels in MSA male patients, which were not considered in
this study. We also found lower serum UA levels in male MSA
patients compared to healthy male subjects; this difference was
not significant in the females. This finding suggests that UA may
be more useful in evaluating MSA in men. The bio-physiological
associations between gender-specific hormones and UA may at
least partly be attributable to a higher occurrence of MSA in men
(Cao et al., 2013).
Hcy demonstrated a strong positive correlation with H&Y and
NMSS (cardiovascular domain) and a negative correlation with
MMSE in MSA patients. This finding strongly suggests that Hcy
significantly influences the motor and non-motor dysfunctions
of MSA patients. One of the purposes of this study is to explore
if the inflammation biomarkers could be used to assess MSA in
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different NMS such as the cardiovascular domain. We noticed a
significant correlation between inflammation biomarkers with the
cardiovascular domain among MSA patients, strongly indicating
that Hcy could be a relatively precise biomarker for NMS when
evaluating MSA patients. Although Hcy is known for being a
high risk factor for cardiovascular disease, our current study of
47 MSA patients only showed that 2 patients presented with mild
T-wave depression in the ECG examination (data not shown).
Moreover, none of the MSA patients displayed abnormal serum
levels of creatine kinase (CK), CK-isoenzyme (CK-MB), myocar-
dial enzymes (MGB), lactate dehydrogenase (LDH), and LDH
isoenzyme (data not shown), which aremarkers for cardiovascular
disease. This emphasizes the fact MSA patients do not necessarily
present with cardiovascular diseases, and that Hcy would be a
reliable biomarker for the cardiovascular aspect in MSA. Serum
Hcy levels also have a relationship with neuropsychiatric dis-
eases such as depression (Bjelland et al., 2003). Several reports
have suggested a close relationship between Hcy and hippocam-
pus atrophy in alcoholic patients, suggesting that Hcy may have
an effect on cognitive function (Kurth et al., 2004; Shimomura
et al., 2011). Our previous studies indicate that cognitive function
is closely associated with neurotransmitter receptors, especially
NMDA receptors in the hippocampus, caudate putamen, nucleus
accumbens, cingulate cortex, and other areas in the brain (Xu
et al., 2012; Wang et al., 2014). In fact, Hcy could constantly
activate NMDA receptors to result in neurotoxicity (Boldyrev
et al., 2013). Taken together, these studies indicate that Hcy may
have an influence on the decreased cognition in MSA patients via
a change in hippocampus volume and the modulation of NMDA
receptors in the hippocampus. Interestingly, our results showed
that serum UA had no significant correlation with the severity of
both motor and non-motor dysfunctions in MSA patients. This
finding implies that the relationship of UA with the development
and exacerbation of MSA may not be clear. Based on this finding,
we hypothesize that UA may have an important function in the
pathogenesis (but not in the progression) of MSA. The results
of our study strongly indicate that as common inflammatory
mediators, Hcy, but not UA, may contribute to the prevalence and
exacerbation of the disease.
Although screening tools such as MRI maybe useful in detect-
ing late-stage MSA, it lacks the sensitivity in detecting early stage
MSA. There remains a need to use more sensitive tools such
as serum Hcy and UA measurements when screening for early
stage MSA. Our ROC data yielded an AUC of 0.709 for Hcy and
0.638 for UA. These findings indicate an acceptable sensitivity
and specificity of Hcy and UA in the potential discrimination of
MSA. Notably, Hcy displays more reliable discrimination when
compared to UA (Figures 3B,C). Moreover, one of the most
notable findings in the current study showed that the combination
of Hcy and UA exhibited a better discriminatory ability, with an
AUCof 0.736, comparedwithHcy orUA alone. The reliability and
potential utility of combined Hcy and UA as diagnostic biomark-
ers in plasma for screening MSA is reflected in the ROC analysis.
Our findings have important clinical relevance.With the use of the
serum Hcy and UA as a screening tool, clinicians will potentially
be able to detect MSA and easily screen early stage MSA patients.
However, we must acknowledge that there may be a significant
overlap between the serum levels of Hcy and UA in MSA and
normal controls. This finding suggests that eitherHcy orUA alone
is not a reliable diagnostic predictor.
There are several limitations to our study, which should not
be ignored: (1) a small number of participants (47 MSA, 60 PD,
and 50 normal subjects) were recruited; (2) most patients with
MSA are at early stages of the disease, with a low median stage
of the UMSARS and a relatively high MMSE score (25.32 3.42);
(3) genetic factors such as the MTHFR genotype and folate or
vitamin B12 administration were not considered in this study;
(4) to validate and complete the questionnaire, we only chose
MSA patients with sufficient cognitive ability; this significantly
narrowed the population in the study. The above criteria (1–4) in
the population chosenmay have resulted in a bias for Hcy and UA
levels in MSA patients. Therefore, it is necessary to conduct large
population studies in the future. Furthermore, different stages of
MSA patients in both UMSARS-IV and MMSE scores should be
included to compensate for the limitations in the current study.
In summary, the current study supports the notion that inflam-
mation contributes to the pathogenesis ofMSA.Of the biomarkers
studied (CRP, Hcy, and UA), Hcy was the most suitable and
reliable inflammatory mediator in evaluating the severity of MSA.
Based on this study, it is reasonable to speculate that high lev-
els of serum Hcy may negatively impact MSA patients through
various mechanisms, including generation of oxidative stress and
persistent activation of NMDA receptors in the brain. The inflam-
matory biomarker Hcy, which distinguishes MSA patients from
normal subjects, is important as it provides a testable hypothesis
related to the pathophysiology of MSA. Furthermore, high levels
of serum Hcy may predispose patients to the progressive stages
in both motor and non-motor dysfunctions. The ROC curve, in
combination with serum Hcy and UA, would be valuable for the
early diagnosis of MSA; this method could be used to increase
the diagnostic accuracy for differentiating MSA subjects from
healthy subjects. Our findings support the use of serum Hcy and
UA to diagnoseMSA, but neuropathological correlation would be
required to confirm this. To our best knowledge, this is the first
study to consider the combination of serum Hcy and UA levels in
diagnosing and assessing the severity of MSA. Further studies are
needed to determine whether serum Hcy and UA abnormalities
are indeed reliable parameters in discriminating MSA from PD,
particularly in the early stages of MSA.
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